Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)

Merck Sharp & Dohme (MSD)

Status and phase

Withdrawn

Phase 4

Conditions

Pyoderma

Treatments

Drug: sisomicin

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT00202891

P04460

Details and patient eligibility

About

This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the treatment of Indian patients with primary pyodermas.

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients of either sex and suffering from primary pyodermas requiring topical antibiotic therapy without occlusive dressings.
>=6 years of age.
Written informed consent.

Exclusion criteria

Patients must not take any other antibiotics.
Patients should not be hypersensitive to any of the test drugs.
Patients are not to have any other investigational drug within one month of starting this study.
Patients cannot be enrolled more than once in the study.
Patients must not have any significant medical condition which, in the judgment of the investigator, might interfere with the study or require treatment.
Pregnant women and nursing mothers are to be excluded.